← SynDRA
OXCARBAZEPINE
SynDRA canonical compound SYN0003493 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | SCN5A |
|---|
| Mechanism of action | Sodium channel blocker |
|---|
| Indication | seizures |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- SCN5A
- SCN11A
- SCN1A
- SCN3A
- SCN10A
- SCN2A
- SCN4A
- SCN7A
- SCN8A
- SCN9A
- CYP2C19
- CYP3A4
Mechanisms of action (all sources)
- Sodium channel blocker
- SCN1A BLOCKER
- Sodium channel alpha subunit blocker
- SCN5A BLOCKER
- SCN4A BLOCKER
- SCN7A BLOCKER
- SCN2A BLOCKER
- SCN9A BLOCKER
- SCN3A BLOCKER
- SCN11A BLOCKER
- SCN8A BLOCKER
- SCN10A BLOCKER
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- DRD2
- HDAC6
- NPY2R
- NPY1R
- MMP9
- MMP1
- MC5R
- MC4R
- MC3R
- MAPT
- MAPK3
- MAPK14
- MAPK1
- ACHE
- MAOA
- LCK
- KMT2A
- KDM4E
- KCNH2
- HTR6
- HTR2C
- HTR2B
- HTR2A
- HRH2
- HRH1
- NR3C1
- OPRD1
- OPRK1
- SLC6A2
- VDR
- USP1
- TDP1
- TBXAS1
- TACR2
- TACR1
- SLCO1B3
- SLCO1B1
- SLC6A4
- SLC6A3
- SIGMAR1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP1A2
- G3P
- IF4H
- KCMB1
- KCMB2
- MRGPRX1
- PABP1
Drug classes
- Anticonvulsants
- Cardiovascular Agents
- Central Nervous System Agents
- Cytochrome P-450 CYP3A Inducers
- Membrane Transport Modulators
- Metabolic Side Effects of Drugs and Substances
- Sodium Channel Blockers
- Voltage-Gated Sodium Channel Blockers
- Anti-epileptic Agent
ATC classes
Cross-references
Synonyms
- OXTELLAR XR
- TRILEPTAL
- Trileptal
- oxacarbazepine
- oxecarb
- oxetol
- Oxcarbazepina
- Oxcarbamazepine
- GP-47680
- KIN-493
- NSC-758693
- SPN-804
- Oxtellar xr
- Epilexter
- Epliga
- Oxacarbazepine
- Oxcarbazepime
- Oxcarbazepinum
- Timox
- Desitin brand of oxcarbazepine
- Novartis brand of oxcarbazepine
- Oxcarbazepine [INN]
- O0363
- Oxaleptal (TN)
- Oxcarbazepina [INN-Spanish]
- Oxcarbazepinum [INN-Latin]
- Trileptal (TN)
- Oxcarbazepine (USAN/INN)
- Oxtellar XR
- MLS000084586
- NSC 758693
- CHEMBL1068
- SMR000048684
- CHEBI:7824
- VZI5B1W380
- NCGC00065934-02
- CAS-28721-07-5
Reported adverse events
- Hypersensitivity
- Stevens-Johnson syndrome
- Somnolence
- Angioedema
- Asthenia
- Ataxia
- Diplopia
- Fatigue
- Rash
- Vertigo
- Vomiting
- Acne
Look up OXCARBAZEPINE in the interactive SynDRA portal →